Material Insights · Understanding the Material World

Monoclonal antibodies: Overview

What it does

The job the technology does for people, in a short paragraph

Monoclonal antibodies are identical antibodies that all bind one chosen target molecule. Doctors use them as medicines against cancers, autoimmune diseases and infections, and laboratories use them in tests and to purify substances [1][2]. The method dates from 1975 [1]; the first antibody medicine was approved in 1986 [2], and more than 200 were on the market by 2025 [3].

as of 2026-11-11

How it works

The working principle in plain words, step by step

The immune system makes antibodies, Y-shaped proteins whose tips fit one particular shape on a germ or a cell [4]. Each antibody-making white blood cell makes just one kind, but such cells die quickly outside the body. Köhler and Milstein fused them with long-lived tumour cells [1]. Each fused cell, a hybridoma, keeps making its parent's single antibody and can be grown without limit. Picking the one hybridoma whose antibody fits the target gives a lasting source of identical antibodies. Early antibodies came from mice, and patients' immune systems reacted against them [2]. Genetic engineering then replaced more and more of the mouse protein with human sequence, giving chimeric, humanised and fully human antibodies [2].

as of 2026-11-11

Key figures

The handful of numbers that size it up, each with its unit, year and source

FigureValueUnitYearSource
Marketed antibody therapeutics, more than200medicines2025[3]
Antibody therapeutics with a first approval in 202421medicines2024[3]
World therapeutic monoclonal antibody market115.2billion USD2018[2]
Sales of adalimumab, the best-selling drug, nearly19.9billion USD2018[2]
Antibody therapeutics in the late-stage pipeline178medicines2025[3]
Share of licensed antibody medicines sold in the US, Europe and Canada, about80%2020[6]

as of 2026-11-11

Where it is used

The main places and products the technology is found in

  • Cancer treatment, alone or carrying a drug to the tumour
  • Autoimmune diseases such as rheumatoid arthritis
  • Prevention of transplant rejection
  • Infectious diseases
  • Diagnostic tests and laboratory research

as of 2026-11-11

Scale today

How much of it there is now: units in use, made each year and who uses it

Installed
More than 200 marketed antibody therapeutics [3]
Unit
medicines
Year
2025
Note
Counts approved medicines, not doses or patients; the latest market value found is for 2018 [2].

as of 2026-11-11

Sources

  1. The Nobel Prize in Physiology or Medicine 1984: press release Nobel Assembly at Karolinska Institutet (nobelprize.org)
  2. Development of therapeutic antibodies for the treatment of diseases Journal of Biomedical Science 27: 1 (Lu, Hwang, Liu, Lee, Tsai, Li and Wu), on PubMed Central, 2020
  3. Antibodies to watch in 2025 mAbs 17(1): 2443538 (Crescioli, Kaplon, Wang, Visweswaraiah, Kapoor and Reichert), record at Washington University in St. Louis, 2025
  4. The Nobel Prize in Physiology or Medicine 1972 - Press release Nobel Assembly at Karolinska Institutet (nobelprize.org), 1972
  5. IAVI and Wellcome issue a global call to action: Monoclonal antibodies for COVID-19 and other diseases could save millions of lives IAVI and Wellcome, 2020